ArticleEsophagus : official journal of the Japan Esophageal Society2026
Clinicopathological features in T1 adenocarcinoma of the esophagogastric junction: a new perspective on tumor localization.
Article in Esophagus : official journal of the Japan Esophageal Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional classifications of T1 adenocarcinoma at the esophagogastric junction (T1-AEGJ) rely on lymph node metastasis patterns and define AEGJ according to the distance between the tumor epicenter and esophagogastric junction (EGJ). However, their significance in T1-AEGJs remains unclear due to the low frequency of lymph node metastasis. Thus, classifications based solely on tumor epicenter may encompass tumors with distinct biological behaviors, particularly those in the stomach. Therefore, we aimed to elucidate the characteristics of T1-AEGJs localized in the stomach.
methodsWe retrospectively analyzed 266 patients with pT1-AEGJs who underwent endoscopic or surgical resection between 2010 and 2023. Tumors were classified into Groups E (confined to the esophagus or crossing the EGJ) and G (localized in the stomach). Clinicopathological features were compared between the groups, and risk factors for deep submucosal invasion (SM > 500 μm) were evaluated using multivariate analysis.
resultsPatients in Group G were older and had a higher prevalence of Helicobacter pylori infection (64.9% vs. 30.8%) and intestinal metaplasia (71.6% vs. 43.1%). Conversely, patients in Group E had more incidences of hiatal hernia (42.5% vs. 20.3%), gastroesophageal reflux disease (43.4% vs. 22.4%), Barrett's esophagus (47.6% vs. 9.0%), and deep submucosal invasion (45.4% vs. 27.8%). Tumor size ≥ 20 mm, EGJ extension, depressed or protruded morphology, and undifferentiated biopsy histology were identified as independent risk factors for deep invasion.
conclusionsT1-AEGJ tumors in the stomach demonstrate distinct clinicopathological features. Therefore, a classification based on EGJ extension, and not just epicenter, may improve their risk assessment and treatment decisions.
Indexed as
Identifiers
41942757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.